The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
A Phase I/II Study of Herpes Simplex Virus Type 1 Thymidine Kinase "Suicide" Gene Therapy for Recurrent Glioblastoma
Abstract
Despite extensive surgery for glioblastoma, residual tumor cells always lead to relapse. Gene therapy based on retrovirus-mediated gene transfer of herpes simplex virus type 1 thymidine kinase (HSV-1 TK), which specifically sensitizes dividing cells to ganciclovir (GCV) toxicity, may help eradicate such cells. During glioblastoma surgery, HSV-1 TK retroviral vector-producing cells (M11) were injected into the surgical cavity margins after tumor debulking. After a 7-day transduction period, GCV was administered for 14 days. Safety was assessed by clinical and laboratory evaluations, and efficacy was assessed by MRI-based relapse-free survival at month 4 and by overall survival. Twelve patients with recurrent glioblastoma were treated without serious adverse events related to M11 cell administration or GCV. Quality of life was not negatively influenced by this treatment. Overall median survival was 206 days, with 25% of the patients surviving longer than 12 months. At 4 months after treatment, 4 of 12 patients had no recurrence; their median overall survival was 528 days, compared with 194 days for patients with recurrence (p = 0.03 by the log rank test). One patient is still free of detectable recurrence, steroid free and independent, 2.8 years after treatment. Thus, brain injections of M11 retroviral vector-producing cells for glioblastoma HSV-1 TK gene therapy were well tolerated and associated with significant therapeutic responses. These results warrant further development of this therapeutic strategy in brain tumor, including recurrent glioblastoma. Expression of the herpes simplex virus type 1 thymidine kinase specifically sensitizes transduced and bystander cancer cell to ganciclovir toxicity. Suicide gene therapy based on HSV-1 TK gene transfer has demonstrated significant tumoricidal effect at nontoxic doses in many preclinical models, including melanoma and brain tumors. We report here the results of a phase I/II clinical trial based on in situ administration of HSV-1 TK retroviral vector-producing cells for recombinant glioblastoma. The treatment was well tolerated and associated with significant therapeutic responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Walker, M. D., Alexander, E., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Mealey, J., Norrell, H. A., Owens, G., Ransohoff, J., Wilson, C. B., et al. (1978) · Journal of Neurosurgery · doi:10.3171/jns.1978.49.3.0333 · Cited by 1,667
The New WHO Classification of Brain Tumours
Kleihues, P., Burger, P. C., & Scheithauer, B. W. (1993) · Brain Pathology · doi:10.1111/j.1750-3639.1993.tb00752.x · Cited by 1,587
Culver, K. W., Ram, Z., Wallbridge, S., Ishii, H., Oldfield, E. H., & Blaese, R. M. (1992) · Science · doi:10.1126/science.1317968 · Cited by 1,509
Brem, H., Piantadosi, S., Burger, P. C., Walker, M., Selker, R., Vick, N. A., Black, K., Sisti, M., Brem, S., Mohr, G., et al. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90755-6 · Cited by 1,389
The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.
Freeman, S. M., Abboud, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., & Abraham, G. N. (1993) · PubMed · Cited by 1,084
Moolten, F. L. (1986) · PubMed · Cited by 972
Grading of astrocytomas: A simple and reproducible method
Daumas-Duport, C., Scheithauer, B., O'Fallon, J., & Kelly, P. (1988) · Cancer · doi:10.1002/1097-0142(19881115)62:10<2152::aid-cncr2820621015>3.0.co;2-t · Cited by 891
Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J. J., DeVroom, H. L., Otto, E., Long, Z., Chiang, Y., McGarrity, G. J., Muul, L. M., et al. (1997) · Nature Medicine · doi:10.1038/nm1297-1354 · Cited by 668
Innis, M. A., & Gelfand, D. H. (1990) · PCR Protocols · doi:10.1016/b978-0-12-372180-8.50005-6 · Cited by 632
Warnke, P. C., Kreth, F. W., & Ostertag, C. B. (1995) · Neurosurgery · doi:10.1097/00006123-199504000-00044 · Cited by 483
Cited by
Rainov, N. G. (2000) · Human Gene Therapy · doi:10.1089/104303400750038499 · Cited by 698
Dewey, R. A., Morrissey, G., Cowsill, C. M., Stone, D., Bolognani, F., Dodd, N. J. F., Southgate, T. D., Klatzmann, D., Lassmann, H., Castro, M. G., et al. (1999) · Nature Medicine · doi:10.1038/15207 · Cited by 311
Self-citationConvection-enhanced delivery of nanocarriers for the treatment of brain tumors
Allard, E., Passirani, C., & Benoit, J.-P. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.01.003 · Cited by 294
Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives
Greco, O., & Dachs, G. U. (2001) · Journal of Cellular Physiology · doi:10.1002/1097-4652(2001)9999:9999<::aid-jcp1060>3.0.co;2-h · Cited by 273
In Vivo Tracking of Stem Cells for Clinical Trials in Cardiovascular Disease
Frangioni, J. V., & Hajjar, R. J. (2004) · Circulation · doi:10.1161/01.cir.0000149840.46523.fc · Cited by 269
Metadata
- Authors
- Klatzmann, D., Valery, C. A., Bensimon, G., Marro, B., Boyer, O., Mokhtari, K., Diquet, B., Salzmann, J.-L., Philippon, J., & Glioblastoma, S. G. O. G. T. F.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 1998-11-20
- Volume
- 9
- Issue
- 17
- Pages
- 2595-2604
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2082590590
- Cited by
- 269
- References
- 24
- FWCI
- 11.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase I/II Study of Herpes Simplex Virus Type 1 Thymidine Kinase "Suicide" Gene Therapy for Recurrent Glioblastoma. https://app.cochat.ai/papers/10.1089/10430349850019436
- The paper
- Klatzmann, D., Valery, C. A., Bensimon, G., Marro, B., Boyer, O., Mokhtari, K., Diquet, B., Salzmann, J.-L., Philippon, J., & Glioblastoma, S. G. O. G. T. F. (1998). A Phase I/II Study of Herpes Simplex Virus Type 1 Thymidine Kinase "Suicide" Gene Therapy for Recurrent Glioblastoma. Human Gene Therapy. https://doi.org/10.1089/10430349850019436
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.